[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562464":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Centre Francois Baclesse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"tumour and blood collection",null,"tumour and blood collection for realization ex vivo organoid models",[13],"Other: tumour and blood samples",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"tumour and blood samples","Tumour and blood samples",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Gwenn LE GALL, Medical Doctor","CONTACT","+33231455050","g.legall@baclesse.unicancer.fr",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"François CHERIFI, Medical Doctor","33231455050","f.cherifi@baclesse.unicancer.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Centre François Baclesse","RECRUITING","Caen","France","FR",{"type":37,"coordinates":38},"Point",[39,40],-0.35912,49.18585,{"lat":40,"lon":39},[43],{"name":21,"role":22,"phone":44,"phoneExt":10,"email":24},"332031455050",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100562464",false,"NCT06603506","Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study","PENDOR","Inclusion Criteria:\n\n* Patient aged 18 years or more\n* Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.\n* Patient with localized endometrial cancer, presenting:\n\n  * A high-grade endometrioid histological type and\u002For\n  * P53 mutation and\u002For\n  * a non-endometrioid histological type regardless of P53 status.\n* Patient affiliated to a social security scheme\n* Information and signature of informed consent prior to any specific study procedure\n\nExclusion Criteria:\n\n* Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).\n* Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.","FEMALE","18 Years",{"count":56,"type":57},16,"ESTIMATED","OBSERVATIONAL","This study comprises 3 stages:\n\n1. Collection of tumor and blood samples.\n2. Creation of organoid models based on tumor samples.\n3. Development of functional tests to predict clinical response to treatment.",[61],"Endometrial Cancer",[63,64,65],"endometrial cancer","organoide","PARP inhibitor","2024-11-25",{"date":68,"type":69},"2024-11-26","ACTUAL",{"date":71,"type":69},"2024-11-21",{"date":73,"type":57},"2027-10-15",{"name":5,"class":6},1]